top of page

Green Heart Growth 

CBD Clinical Studies and Publications

Looking for more Cannabis Information? is an excellent resource for CBD & THC research, clinical trials and more. 

NCBI  |  US National Library of Medicine  |  National Institutes of Health

Below is the cited reference list from Sean M. Westmeier's Cannabidiol (CBD) Review - Potential Benefits Relating to Functional, Healthy Balance

If you're looking for more information on Cannabidiol (CBD) and Potential Therapeutic Benefits Relating to Issues with Sleep, Anxiety, Headaches, Migraines, Hangovers, Arthritis, Allergies we Highly Recommend checking the Source of the Cited Articles. Go to the Source and Learn More. We all are!

Bih, C.I., et al., Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics, 2015. 12(4): p. 699-730.


Machado Bergamaschi, M., et al., Safety and Side Effects of Cannabidiol, a Cannabis Sativa Constituent. Current Drug Safety, 2011. 6(4): p. 237-249.

Marks, M.D., et al., Identification of candidate genes affecting Δ(9)- tetrahydrocannabinol biosynthesis in Cannabis sativa. Journal of Experimental Botany, 2009. 60(13): p. 3715-3726.

Jiang, R., et al., Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci, 2011. 89(5-6): p. 165-70. 

Cunetti, L., et al., Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. Transplant Proc, 2018. 50(2): p. 461-464

Hundal, H., et al., The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol, 2018. 32(3): p. 276-282.

Pisanti, S., et al., Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther, 2017. 175: p. 133-150

Devinsky, O., et al., Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014. 55(6): p. 791-802

Irving, P.M., et al., A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis, 2018. 24(4): p.714-724

June 26th, 2018   -  FDA Approved Epidiolex - Created and Sold by GW Pharmaceutical

Fasinu, P.S., et al., Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.  Pharmacotherapy, 2016. 36(7): p. 781-796

Iffland, K. and F. Grotenhermen, An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2017. 2(1): p. 139-154

Pertwee, R., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐ tetrahydrocannabivarin. British journal of pharmacology, 2008. 153(2): p. 199-215

McPartland, J.M., et al., Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 2015. 172(3): p. 737-753 

bottom of page